益佰製藥(600594.SH)完成轉讓醫院管理公司53%股權
格隆匯12月30日丨益佰製藥(600594.SH)公佈,2018年12月13日,公司收到宋士和的《股權收購要約書》,宋士和擬以人民幣6.6億元的價格收購公司所持有控股子公司淮南朝陽醫院管理有限公司(以下簡稱“醫院管理公司”)53%股權。並以其控股的淮南和徽企業管理有限公司(以下簡稱“和徽管理”)作為交易對方進行收購。
2019年12月30日,公司收到了和徽管理支付的第三期股權轉讓價款人民幣1.6億元,收到該款項對公司當期業績不造成影響。截至本公告日,公司已收到全部股權轉讓價款,本次公司轉讓醫院管理有限公司53%股權事宜全部完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.